|
Dabrafenib Clinical Trials
14 actively recruiting trials across 5 locations
Also known as: BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Open cohort, Tafinlar
Other9 trials
Scottsdale, Arizona1 trial
Dabrafenib and/or Trametinib Rollover Study
Honor Health Research Institute
Phase 4
Fort Smith, Arkansas1 trial
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Mercy Hospital Fort Smith
Phase 3
Duarte, California1 trial
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
Phase 1
Iowa City, Iowa1 trial
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Iowa
Phase 1
Boston, Massachusetts1 trial
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.